<DOC>
	<DOCNO>NCT02286882</DOCNO>
	<brief_summary>PF-06409577 new compound propose treatment diabetic nephropathy . The primary purpose study evaluate safety , tolerability , pharmacokinetics single oral dos PF-06409577 healthy adult subject .</brief_summary>
	<brief_title>A Single Oral Dose Study Of PF-06409577 In Healthy Adult Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy male , female subject non childbearing potential . Body Mass Index ( BMI ) 18 30.5 kg/m2 ; total body weight &gt; 50 kg Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Single Ascending Dose</keyword>
	<keyword>healthy subject</keyword>
</DOC>